Filter posts

California Biomedical Companies Cite Lack Of Funding As Major Concern

As I have mentioned in past blog posts, the U.S. bioscience industry has demonstrated stability …

FDASIA: A Step Forward for Patients

Earlier this year, Congress passed and President Obama signed the FDA Safety and Innovation Act …

Public Health at Risk: Don’t Cut Programs that Work

In order to avoid the “fiscal cliff,” the Congress must compromise and protect our economic …

"When Genetic Engineering Came Of Age"

October 29 was the 30th anniversary of the approval by the Food and Drug Administration …

BIO Investor Forum - Raring to Go: The Race to Treat Ultra-Rare Diseases

The signing of FDASIA by President Obama in July reinforces the country’s commitment to fostering …

“Approval of Foods from Genetically Modified Animals is Unjustifiably Slow”

The Los Angeles Times reported on concerns within the U.S. animal biotech industry and the …

FDA Safety and Innovation Act: A Step Forward for Patients With Rare Diseases

By Peter L. Saltonstall, President and CEO, National Organization for Rare Disorders (NORD) The Food …

Biosimilars Ahead, Proceed with Caution

By Richard M. Dolinar, M.D., Chairman, Alliance for Safe Biologic Medicines In today’s budget-constrained world, …

Industry Regulatory Issues to be Highlighted at 2012 BIO International Convention

In the words of BIO’s Andrew Emmett, Managing Director, Science & Regulatory Affairs, ‘2012 is …

What Parallel Review Means for Manufacturers

By Stephen Rothenberg, J.D. and Matt Levy, J.D., Numerof & Associates, Inc. (NAI) Currently, the …